Cargando…

Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health

Accumulating evidence indicates that the gut microbiome is an important regulator of body weight, glucose and lipid metabolism, and inflammatory processes, and may thereby play a key role in the aetiology of obesity, insulin resistance and type 2 diabetes. Interindividual responsiveness to specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jardon, Kelly M, Canfora, Emanuel E, Goossens, Gijs H, Blaak, Ellen E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Recent Advances in Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120404/ https://www.ncbi.nlm.nih.gov/pubmed/35135841 http://dx.doi.org/10.1136/gutjnl-2020-323715

Ejemplares similares

Dietary Patterns Affect the Gut Microbiome—The Link to Risk of Cardiometabolic Diseases
por: Tindall, Alyssa M, et al.
Publicado: (2018)

Interaction between drugs and the gut microbiome
por: Weersma, Rinse K, et al.
Publicado: (2020)

Gut microbiome and health: mechanistic insights
por: de Vos, Willem M, et al.
Publicado: (2022)

Human gut microbiome: hopes, threats and promises
por: Cani, Patrice D
Publicado: (2018)

The vagal innervation of the gut and immune homeostasis
por: Matteoli, Gianluca, et al.
Publicado: (2013)

Role of the microbiome in human development
por: Dominguez-Bello, Maria Gloria, et al.
Publicado: (2019)

Advancing human gut microbiota research by considering gut transit time
por: Procházková, Nicola, et al.
Publicado: (2023)

Effects of gut microbiota manipulation on ex vivo lipolysis in human abdominal subcutaneous adipocytes
por: Jocken, Johan W. E., et al.
Publicado: (2018)

The role of gut microbiota in cancer treatment: friend or foe?
por: Cheng, Wing Yin, et al.
Publicado: (2020)

Gastrointestinal Transit Time, Glucose Homeostasis and Metabolic Health: Modulation by Dietary Fibers
por: Müller, Mattea, et al.
Publicado: (2018)

The gut microbiota and host health: a new clinical frontier
por: Marchesi, Julian R, et al.
Publicado: (2016)

Mucus barrier, mucins and gut microbiota: the expected slimy partners?
por: Paone, Paola, et al.
Publicado: (2020)

Gut microbiota-derived metabolites as central regulators in metabolic disorders
por: Agus, Allison, et al.
Publicado: (2021)

Metabolic phenotyping in people living with obesity: Implications for dietary prevention
por: Blaak, Ellen E., et al.
Publicado: (2023)

Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management
por: Leung, T.F, et al.
Publicado: (2003)

Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts
por: Adolph, Timon E, et al.
Publicado: (2022)

Calprotectin: from biomarker to biological function
por: Jukic, Almina, et al.
Publicado: (2021)

Unraveling the Pathophysiology of Obesity-Related Insulin Resistance—A Perspective on “Adipose Tissue Inflammation Is Directly Linked to Obesity-Induced Insulin Resistance, while Gut Dysbiosis and Mitochondrial Dysfunction Are Not Required”
por: Goossens, Gijs H, et al.
Publicado: (2020)

MicroRNAs: new players in IBD
por: Kalla, R, et al.
Publicado: (2015)

Applications of dual energy CT in clinical practice: A pictorial essay
por: Sanghavi, Parang S, et al.
Publicado: (2019)

MR-guided focused ultrasound surgery: A novel non-invasive technique in the treatment of adenomyosis –18 month's follow-up of 12 cases
por: Dev, Bhawna, et al.
Publicado: (2019)

Mechanisms of rhinovirus-induced asthma
por: Papadopoulos, Nikolaos G, et al.
Publicado: (2004)

Interferon lambdas: the next cytokine storm
por: Kelly, Christabel, et al.
Publicado: (2011)

Gene expression and hepatitis C virus infection
por: Asselah, T, et al.
Publicado: (2009)

Epigenetics in liver disease: from biology to therapeutics
por: Hardy, Timothy, et al.
Publicado: (2016)

Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
por: Hessmann, Elisabeth, et al.
Publicado: (2017)

Liver sampling: a vital window into HBV pathogenesis on the path to functional cure
por: Gill, Upkar S, et al.
Publicado: (2018)

Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
por: Conway, James RW, et al.
Publicado: (2019)

Protease inhibition as new therapeutic strategy for GI diseases
por: Vergnolle, Nathalie
Publicado: (2016)

Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells
por: Powell, Nick, et al.
Publicado: (2020)

Liver organoids: from basic research to therapeutic applications
por: Prior, Nicole, et al.
Publicado: (2019)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

Regulatory T-cell therapy in Crohn’s disease: challenges and advances
por: Clough, Jennie N, et al.
Publicado: (2020)

Niche-specific functional heterogeneity of intestinal resident macrophages
por: Viola, Maria Francesca, et al.
Publicado: (2021)

From the origin of NASH to the future of metabolic fatty liver disease
por: Geier, Andreas, et al.
Publicado: (2021)

Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
por: Ting, Nick Lung-Ngai, et al.
Publicado: (2022)

Immunopathogenesis and environmental triggers in coeliac disease
por: Levescot, Anais, et al.
Publicado: (2022)

Organoids in gastrointestinal diseases: from experimental models to clinical translation
por: Günther, Claudia, et al.
Publicado: (2022)

Microbial transmission, colonisation and succession: from pregnancy to infancy
por: Xiao, Liwen, et al.
Publicado: (2023)

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use
por: van Deuren, Thirza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pmalk8mufc7rjni70c4klcdlnn